Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 02 2022 - 2:40PM
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical
company utilizing its proprietary Precision Timed Release™ (PTR™)
drug delivery platform technology to build and advance a pipeline
of next-generation pharmaceutical products, today announced that
Chairman and CEO Shane J. Schaffer, PharmD, and preeminent
board-certified psychiatrist and Cingulate scientific advisor Dr.
Ann Childress, MD, will participate in a live Benzinga All Access
event on June 3, 2022, at 8:45 a.m. CST.
The discussion will address the current unmet needs in Attention
Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of
Cingulate’s PTR platform into the anxiety therapeutic area. Dr.
Schaffer will also provide a company overview.
The event may be viewed live on Benzinga’s YouTube channel,
Benzinga All Access, and will also be available for viewing on
Cingulate’s website at cingulate.com/investors.
About Cingulate® Cingulate Inc.
(NASDAQ: CING), is a clinical-stage biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, designed to improve the
lives of patients suffering from frequently diagnosed conditions
characterized by burdensome daily dosing regimens and suboptimal
treatment outcomes. With an initial focus on the treatment of
Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is
identifying and evaluating additional therapeutic areas where PTR
technology may be employed to develop future product candidates,
including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For
more information visit Cingulate.com
About Dr. Ann Childress, MDAnn
C. Childress, M.D., a board-certified physician in Psychiatry and
Neurology, specializing in child, adolescent, and adult psychiatry,
has been a practicing psychiatrist for more than 35 years. Dr.
Childress has held numerous prominent positions, including chief of
mental health at various psychiatric hospitals as well as
professorships within prestigious universities. Dr. Childress is
President of the American Professional Society of ADHD and Related
Disorders, Education Director for the Nevada Psychiatric
Association, a distinguished life fellow of the American
Psychiatric Association and a member of the American Academy of
Child and Adolescent Psychiatry.
Dr. Childress is the founder and principal investigator of
Clinical Research of Southern Nevada and is the founder and
president of the Center for Psychiatry and Behavioral Medicine,
both entities located in Las Vegas, Nevada. She has conducted more
than 180 clinical studies, working on most of the major psychiatric
drugs that have been approved over the last few decades by various
major pharmaceutical companies, including Pfizer, Janssen, Shire,
AstraZeneca, and Novartis.
Dr. Childress has been working with Cingulate since 2018,
serving as a key opinion and thought leader, helping design
multiple clinical protocols, and currently serving as the lead
investigator on Cingulate’s Phase 3 Fixed-Dose Study in pediatrics
and adolescents.
Investor Relations Thomas Dalton Head
of Investor & Public Relations,
CingulateTDalton@cingulate.com913-942-2301Matt KrepsDarrow
Associatesmkreps@darrowir.com214-597-8200Media
RelationsMelyssa WeibleElixir Health Public
Relationsmweible@elixirhealthpr.com201-723-5805
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024